Clinical Trials Logo

Hypersensitivity clinical trials

View clinical trials related to Hypersensitivity.

Filter by:

NCT ID: NCT05407012 Recruiting - Allergy;Food Clinical Trials

TRANS-FOODS: Preventing Peanut Allergy Through Improved Understanding of the Transcutaneous Sensitisation Route, Novel Food Processing and Skin Care Adaptations

TRANS-FOODS
Start date: April 5, 2024
Phase: N/A
Study type: Interventional

This project aims to study the immune responses to peanut allergen in those with a skin barrier defect with and without skin massage, specifically it aims to: 1. Establish if peanut allergen components can pass into human skin through regular massage using the peanut protein-containing extract. 2. Clarify whether this effect is amplified in those with an impaired skin barrier (AD and dry skin vs healthy controls). 3. Assess whether peanut protein components can be detected in interstitial skin fluid (ISF) using a suction device. 4. Test whether peanut protein components present in ISF are able to induce activation of basophils in blood of peanut allergic donors. 5. Assess whether the transcutaneous uptake of peanut protein can be reduced by the prior use of a barrier enhancing cream.

NCT ID: NCT05406141 Recruiting - Cow Milk Allergy Clinical Trials

Nutrition Sufficiency, Allergy Efficacy and Safety of Neocate Jr in Children With Food Protein Allergy

Start date: March 30, 2022
Phase: N/A
Study type: Interventional

The main purpose of this study is to evaluate efficacy and safety of an amino acid-based formula Neocate Jr in children with food protein allergy, and to evaluate nutrition sufficiency of Neocate Jr in 1 to 10 years old children with food protein allergy.

NCT ID: NCT05398276 Recruiting - Anxiety Clinical Trials

Behavioral Exposure for Introceptive Tolerance RCT

BE-FIT
Start date: May 3, 2022
Phase: Phase 2
Study type: Interventional

Behavioral Exposure for Interoceptive Tolerance (BE-FIT) is a mechanism-informed behavioral intervention to target exercise anxiety. The three primary components of BE-FIT include: (1) exposure to feared bodily sensations and exercise; (2) prevention of safety behavior use before/during/after exercise, and (3) use of a wrist-worn activity monitor for physical activity (PA) feedback and activity goal setting. Evidence from the investigators' Stage I trial indicated that BE-FIT is feasible, acceptable, and safe and produced reductions in exercise anxiety and increased exercise outcomes (short-term moderate-to-vigorous intensity physical activity and steps/day). The investigators' present aim is to conduct a Stage II randomized-controlled trial to further evaluate the efficacy of BE-FIT in decreasing exercise anxiety in cardiac rehabilitation (CR) patients and examine whether changes in this target yield successive changes in exercise adherence outcomes.

NCT ID: NCT05392881 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Interstitial Lung Disease Research Unit Biobank

ILDRU
Start date: August 9, 2021
Phase:
Study type: Observational [Patient Registry]

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

NCT ID: NCT05392868 Recruiting - Clinical trials for Dentine Hypersensitivity

Managing Dentine Hypersensitivity With Silver Diamine Fluoride on Older Adults

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

Background: Dentine hypersensitivity is a common oral complaint from older adults. It induces pain, affects oral hygiene practice, limits food choices and negatively affects the quality of life. Silver diamine fluoride (SDF) is a desensitizing agent but well-designed clinical trials are lacking. The objective of this study is to evaluate the effectiveness of SDF in reducing dentine hypersensitivity in older Chinese adults. Methods: This is a double-blinded randomised clinical trial recruiting 166 healthy older adults aged 65 or over after having written consent. A trained calibrated examiner will conduct clinical examination and assess dentine hypersensitive using a blast of compressed air delivered from 3-in-1 syringe. Older adults with a tooth with a self-perceived sensitivity score (SS) of 8 or above will be recruited. They will then be block randomised to receive either 38% SDF solution or 5% potassium nitrate every 4 weeks on the exposed root surface of the most hypersensitive tooth. The visible plaque index, bleeding on probing and probing depth (mm) will be recorded on the most hypersensitive tooth. The same examiner will perform clinical examination and assess the dentine hypersensitivity using the same tools and methods at 4-week and 8-week follow-ups. The examiner and older adults will be blinded to treatment allocation. The primary outcome is the percentage of change in SS before and after intervention at 8 weeks. The secondary outcome will be the percentage of change in VPI before and after intervention at 8 weeks. Clinical significance: It will provide evidence to manage dentine hypersensitivity in older adults in clinical care.

NCT ID: NCT05382975 Recruiting - Physical Activity Clinical Trials

A Comprehensive Trauma-sensitive Approach to Physical Activity Promotion in Schools (CSPAP-T)

CSPAP-T
Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Investigators will conduct a hybrid implementation-effectiveness trial of a trauma-adapted Comprehensive School Physical Activity Program (CSPAP) intervention. A clustered stepped wedge design will be used, with the duration of the trial being 3 years.

NCT ID: NCT05378074 Recruiting - Clinical trials for Post-Traumatic Headache

Hypersensitivity to Opening of BKCa Channels in Post-Traumatic Headache

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The aim is to investigate whether opening of large conductance calcium-activated potassium (BKCa) channels induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

NCT ID: NCT05378061 Recruiting - Clinical trials for Post-Traumatic Headache

Hypersensitivity to PACAP-38 in Post-Traumatic Headache

Start date: June 16, 2022
Phase: N/A
Study type: Interventional

The aim is to investigate whether signaling molecule PACAP-38 induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

NCT ID: NCT05367531 Recruiting - Bleeding Clinical Trials

Assessment of Injectable Medication Platforms

Start date: April 30, 2022
Phase: N/A
Study type: Interventional

Background: While medical advances for in-hospital care rapidly evolve, a mainstay of effective pre-hospital care remains the ability to treat medical emergencies such as anaphylaxis, prolonged seizure, overdose, or uncontrolled bleeding, through rapid administration of appropriate medication. Autoinjectors are used globally to deliver medications in a timely manner, often in environments where immediate access to medical facilities is limited. Rapid administration of intramuscular medication delivery is essential where oral or intravenous delivery is either not possible or ineffective. The purpose of the proposed study seeks to determine the efficiency various types of medication injection administration.

NCT ID: NCT05365802 Recruiting - Clinical trials for Interstitial Lung Disease

FAPI PET for Lung Fibrosis

FAPI ILD
Start date: November 16, 2021
Phase: Early Phase 1
Study type: Interventional

This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung. The study will include 30 patients, the upper limit for PET imaging studies conducted under the Radioactive Drug Research Committee (RDRC) purview. Participants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET/CT scan and one High Resolution CT of the lungs. The study is sponsored by Ahmanson Translational Theranostic Division at UCLA.